BioCryst's First Profitable Year Fuels Takeover Speculation, Takeda Tops Buyer List

EarningsM&A · Partnership
โดย 24/7 Wall St.·US·Read original
Summary · why it matters

BioCryst Pharmaceuticals achieved its first full year of profitability in 2025, with second-quarter 2026 revenue rising 34 percent to 218 million dollars, intensifying acquisition speculation. Takeda ranks as the most plausible acquirer because its HAE injectable Takhzyro is directly threatened by BioCryst's pipeline asset navenibart, while AstraZeneca places second through its Alexion rare-disease platform. The company's oral HAE drug Orladeyo generated 158.2 million dollars in quarterly revenue and carries full-year guidance of 625 million to 645 million dollars, and navenibart's pivotal trial data is expected in the third quarter of 2027. BioCryst closed at 9.84 dollars on August 10, 2026, giving it a market capitalization of roughly 2.5 billion dollars, and analysts hold a consensus price target of 20.82 dollars. No deal talks have been confirmed, and private equity interest is seen as secondary to strategic buyers.

Impact on stocks 7

Biotech & Genomic Medicine▲ · 6 stocks
BioCryst Pharmaceuticals Inc
BCRX
▲ PositiveCapitalrelevance

First profitable year and strong revenue growth fuel takeover speculation, with analysts' consensus price target of $20.82.

Takeda Pharmaceutical Co. Ltd.
4502
± MixedCompetitionrelevance

Takeda's Takhzyro is threatened by BioCryst's navenibart, making it a plausible acquirer, but no deal confirmed.

AstraZeneca PLC
AZN
± MixedCompetitionrelevance

Mentioned as a potential acquirer through its Alexion platform, but no deal talks confirmed.

Health Care▲ · 1 stocks

Theme Impact 1

Related news

3

Ascendis Pharma Regains TransCon Metabolic Rights After Novo Nordisk Split

Ascendis Pharma has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform, with management highlighting once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. Control of once-monthly TransCon Semaglutide and other metabolic projects shifts Ascendis from a partner model with Novo Nordisk to running these programs itself, concentrating both the potential upside and the development and commercialization costs inside one balance sheet. The regained rights and the once-monthly TransCon Semaglutide plans are only one part of the Ascendis story, and the company's existing rare endocrine portfolio still centers on YORVIPATH, SKYTROFA, and TransCon CNP or YUVIWEL. Key proof points now sit in the clinic and on the cash line, including formal trial initiation for once-monthly TransCon Semaglutide in obesity and type 2 diabetes, plus any updated R&D and share repurchase commentary at events such as the September 15, 2026 Morgan Stanley conference.
ASNDNOV.XETRA
Biotech & Genomic Medicine
Simply Wall St·1hRead more →
▲

BioMarin Reports Positive Phase 3 VOXZOGO Hypochondroplasia Data and Files sNDA

BioMarin Pharmaceutical reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug's use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The late-stage data cover an indication with no approved treatments, and the company said the combination of the results and the board appointment underscores its focus on deepening its rare disease franchise and scientific oversight. BioMarin's narrative projects $5.0 billion revenue and $1.3 billion earnings by 2029, requiring 14.0% yearly revenue growth and about a $1.2 billion earnings increase from $73.0 million today, with a $91.42 fair value cited, a 43% upside to its current price. More pessimistic analysts warn that heavy reliance on a few rare disease drugs and uncertainty around future indications could leave BioMarin short of pre-news expectations of about US$4.7 billion in revenue and roughly US$509.5 million in earnings by 2029.
BMRN ▲
Biotech & Genomic Medicine ▲
Simply Wall St·3hRead more →
▲

BioMarin Targets $200 Million Amicus Synergies as VOXZOGO Nears $1 Billion

BioMarin Pharmaceutical said it is progressing with the integration of Amicus Therapeutics and expects $200 million in annual non-GAAP cost savings, with most synergies realized in 2027 and full realization in 2028. Speaking at Morgan Stanley's Global Healthcare Conference, President and CEO Alexander Hardy said Amicus had about 505 employees and BioMarin expects to retain approximately 192 over the long term, with about 70% of the savings coming from general and administrative expenses and the remainder from duplicated research and development functions. Chief Financial Officer Brian Mueller said the deal should be accretive in its first year, with substantial accretion beginning next year, and that leverage is now expected to fall below 2.5 times by the middle of 2027, nearly a year earlier than the initial target. Hardy said VOXZOGO delivered 20% quarterly patient growth despite U.S. competition and is expected to reach $1 billion in revenue this year, which would make it BioMarin's first blockbuster product, while a potential FDA approval in hypochondroplasia is not incorporated into its 2026 outlook. BioMarin projects peak sales of approximately $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI + OPFOLDA by the mid-2030s, and said PALYNZIQ grew 27% to $135 million while VIMIZIM has the potential to exceed $1 billion in revenue.
BMRN ▲
Biotech & Genomic Medicine ▲
MarketBeat·18hRead more →
© 2026 MarketDXNews